Conventional or Video-Assisted Surgery in Treating Patients With Lung Metastases
RATIONALE: Video-assisted surgery may have fewer side effects than conventional surgery in patients with lung metastases. It is not yet known whether conventional surgery or video-assisted surgery is more effective in treating lung metastases. PURPOSE: Randomized phase III trial to compare the effectiveness of conventional surgery with that of video-assisted surgery in treating patients who have lung metastases.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Jul 12, 2016 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- Alliance for Clinical Trials in Oncology
- Interventions being studied
- Procedure: surgical procedure
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
DISEASE CHARACTERISTICS: Histologically confirmed pulmonary metastases (unilateral or bilateral) identified by spiral CT scan No primary lung cancer Documented previous cancer with no history of prior metastasectomy Primary tumor must be definitively controlled No evidence of primary tumor recurrence, either locally or systemically No extrapulmonary metastatic disease or evidence of mediastinal lymph node involvement Lymph nodes greater than 1.0 cm on CT scan must be proven to be benign by tissue biopsy (mediastinoscopy) All lesions must be amenable to minimally invasive resection Must be amenable to video-assisted thoracic surgery with curative intent (complete removal of all documented lesions) No greater than 4 lesions PATIENT CHARACTERISTICS: Age: Over 18 Performance status: CALGB 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Pulmonary: See Disease Characteristics PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: See Disease Characteristics
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of California San Diego Cancer CenterLa Jolla, California
- UCSF Cancer Center and Cancer Research InstituteSan Francisco, California
- Veterans Affairs Medical Center - San FranciscoSan Francisco, California
- CCOP - Christiana Care Health ServicesWilmington, Delaware
- Lombardi Cancer Center, Georgetown UniversityWashington D.C., District of Columbia
- Walter Reed Army Medical CenterWashington D.C., District of Columbia
- CCOP - Mount Sinai Medical CenterMiami Beach, Florida
- University of Illinois at Chicago Health Sciences CenterChicago, Illinois
- Veterans Affairs Medical Center - Chicago (Westside Hospital)Chicago, Illinois
- University of Chicago Cancer Research CenterChicago, Illinois
- University of Iowa Hospitals and ClinicsIowa City, Iowa
- Veterans Affairs Medical Center - TogusTogus, Maine
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 12, 2016. Always confirm current availability with the study team.